The information at September 30, 2006 and for the three and nine month periods ended September 30, 20 is unaudited but includes all adjustments (consisting only of normal recurring adjustments) All significant intercompany accounts and transactions have beenĮliminated in consolidation. Certain disclosures required for complete annual financial statements are not included herein. Regulations of the Securities and Exchange Commission (SEC) pertaining to Form 10-Q. generally accepted accounting principles for interim financial information and pursuant to the rules and and its wholly owned subsidiaries (the Company), and have been prepared in accordance with U.S. The accompanying unaudited consolidated financial statements include theĪccounts of Auxilium Pharmaceuticals, Inc. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTSġ. Unrealized loss on available for sale securities Reclassification of deferred compensation Public offering, net of transaction costsĬashless exercise of common stock warrants Increase (decrease) in cash and cash equivalentsĬash and cash equivalents, beginning of period Net cash provided by financing activities Proceeds from exercise of common stock options Proceeds from financing-related liability
Proceeds from shares issued in private placement, net of transaction costs net of transaction costs Proceeds from shares issued in public offering, net of transaction costs net of transaction costs Net cash provided by (used in) investing activities Interest income accrued on notes receivablefrom stockholdersĬhange in fair value of financing-related liabilityĬhanges in operating assets and liabilities: Weighted average common shares outstandingĪdjustments to reconcile net loss to net cashused in operating activities: See accompanying notes to consolidated financial statements.īasic and diluted net loss per common share Total liabilities and stockholders equity Treasury stock at cost: 13,377 shares at September 30, 2006 Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstandingĬommon stock, $0.01 par value per share authorized 120,000,000 shares issued 35,307,688 and 29,241,482 shares at September 30, 2006 and Prepaid expenses and other current assets (In thousands, except share and per share amounts) Unregistered Sales of Equity Securities and Use of ProceedsĪUXILIUM PHARMACEUTICALS, INC. Quantitative and Qualitative Disclosures About Market Risk Managements Discussion and Analysis of Financial Condition and Results of Operations Notes to Consolidated Financial Statements Yes ¨ No xĪs of November 1, 2006, the number of shares outstanding of the issuers commonĬonsolidated Statement of Stockholders Equity Indicate by check mark whether the registrant is a shell company (as defined in See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. Indicate by check mark whether the registrant is a large accelerated filer, anĪccelerated filer, or a non-accelerated filer. (2) has been subject to such filing requirements for the past 90 days. (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and Indicate by check mark whether the registrant (Registrants telephone number, including area code) (Address of principal executive offices) (Zip Code) (Exact name of registrant as specified in its charter)Ĥ0 Valley Stream Parkway, Malvern, PA 19355 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934įor the quarterly period ended September 30, 2006
0 kommentar(er)
